The success of Sildenafil initially fueled a surge for major pharmaceutical companies, but recent developments present a complicated picture for shareholders. Generic alternatives are eroding profits, and ongoing legal https://louisetisw656583.acidblog.net/72434436/the-blue-pill-and-pharma-a-risky-bet